Premium
Once‐daily metoprolol in primary hypertension
Author(s) -
Karlberg Bengt E.,
Nilsson Ove,
Tolagen Kerstin,
Nitelius Eva,
Waern Urban
Publication year - 1979
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1979254399
Subject(s) - metoprolol , plasma renin activity , medicine , blood pressure , aldosterone , placebo , essential hypertension , heart rate , endocrinology , renin–angiotensin system , alternative medicine , pathology
The antihypertensive effect of the selective beta‐1‐adrenoceptor blocker, metoprolol, administered once daily was evaluated in 32 patients with primary hypertension. After a 4‐wk placebo period, the patients were treated with either 150 mg or 300 mg of metoprolol, once daily, for 8 wk. Initially and during the treatment periods blood was drawn for analysis of metoprolol in plasma, plasma renin activity (PRA), and electrolytes, and urine was collected for determination of the urinary aldosterone excretion. Metoprolol reduced the blood pressure measured up to 26 hr after the last dose. The percentage of responders to metoprolol (decrease of mean arterial pressure ≥10% over placebo) was 40% for patients on 150 mg and 71 % for patients on 300 mg. Except in the standing position, heart rates were reduced for 26 hr after a 150‐mg dose. There was a correlation between pretreatment PRA levels and antihypertensive effect of metoprolol in patients on 300 mg metoprolol but not in patients on 150 mg. Urinary aldosterone decreased equally during treatment in responders and nonresponders. Antihypertensive effects and side effects did not correlate with plasma metoprolol concentrations.